• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Traditional vs. Pragmatic: Changing the Trial Model with Real-World Evidence

Traditional vs. Pragmatic: Changing the Trial Model with Real-World Evidence

RWEGraphic12720-360x240.png
January 24, 2020
Leslie Ramsey

Studies based on real-world evidence (RWE) don’t have to be a replacement for randomized clinical trials but rather an integral part of an overall trial strategy.

Both pragmatic and randomized trials have their pros and cons, but when combined they can produce more effective results. “I think using both of these to provide evidence to the regulators will be where we go in the future,” said Francis Kendall, senior director at Cytel.

You could conduct one or two small phase 1 or 2 trials to show safety and efficacy, he suggested, then apply machine learning and analytics to data on the full targeted population to confirm results. “And if things are not going quite to plan, that’s when you bring in a controlled trial” as backup.

The pragmatic approach is especially beneficial with hard-to-reach populations and studies of rare diseases with a limited number of patients. Registry data and electronic health records can provide evidence where a randomized clinical trial might not be possible.

Other benefits of using data generated in pragmatic trials include:

  • Using predictive analytics to identify candidates for clinical trials;
  • Getting a closer and earlier look at the “average patient;”
  • Developing biomarkers to support outcomes;
  • Optimizing protocols; and
  • Targeting patients and physicians for recruitment.

“Everybody’s starting to use information in different ways, and we have to think about how the clinical development process is actually changing to adapt to these different sources of data,” Kendall said.

Kendall also said that as the population ages, it will be more important to understand patients’ development and journey through healthcare. “We can’t just do clinical trials. We need real-world evidence to have a look at that,” he added.

“Data science in pharma is more than clinical development, is more than just looking at evidence for efficacy … and then safety,” Kendall said. “It’s about targeting patients, understanding patients’ journeys and really helping the patient, putting the patient at the center.”

A survey conducted by the Tufts Center for the Study of Drug Development shows sponsors value RWE the most for the insights it provides into therapeutic area needs, market access and drug effectiveness (CenterWatch Weekly, Aug. 26, 2019). Survey respondents also said they use RWE to improve trial design, improve the safety of marketed drugs and gain a faster regulatory response to their applications.

“I can see in the future, the regulators will want to see … evidence of not only the clinical trial, but maybe a pragmatic clinical trial, or at least a trial done in different settings of standard of care,” Kendall predicted. But drug developers have not yet fully taken the plunge. “We can see some evidence of pharma interest in the mix, but they’re still dipping their toe in the water.”

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing